Premium
Enhancing our chances of picking a winner in higher‐risk myelodysplastic syndromes
Author(s) -
Wei Andrew H.,
Seymour John F.
Publication year - 2022
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.18240
Subject(s) - myelodysplastic syndromes , medicine , immunology , bone marrow
Summary Hypomethylating agents remain the current standard of care for patients with higher‐risk myelodysplastic syndromes. Adès et al. report outcomes from a randomised ‘pick‐a‐winner’ study design that examined the addition of either lenalidomide, valproic acid or idarubicin in combination with azacitidine, compared to azacitidine alone. Commentary on: Adès et al. A randomised phase II study of azacitidine (AZA) alone or with lenalidomide (LEN), valproic acid (VPA) or idarubicin (IDA) in higher‐risk MDS: GFM’s ‘pick a winner’ trial, with the impact of somatic mutations. Br J Haematol 2022;198:535‐544.